Structure Therapeutics (NASDAQ:GPCR) Earns “Buy” Rating from HC Wainwright

Structure Therapeutics (NASDAQ:GPCR)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They currently have a $80.00 price target on the stock. HC Wainwright’s price objective indicates a potential upside of 169.00% from the company’s current price.

GPCR has been the topic of several other reports. Cantor Fitzgerald restated an “overweight” rating and set a $65.00 target price on shares of Structure Therapeutics in a report on Monday, September 23rd. JMP Securities reiterated a “market outperform” rating and issued a $91.00 price objective on shares of Structure Therapeutics in a research report on Wednesday. Finally, Morgan Stanley started coverage on Structure Therapeutics in a research report on Monday, September 23rd. They issued an “overweight” rating and a $118.00 target price on the stock. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Structure Therapeutics has a consensus rating of “Buy” and a consensus price target of $86.50.

Structure Therapeutics Stock Performance

Shares of GPCR stock traded up $1.84 on Thursday, reaching $29.74. 558,899 shares of the company were exchanged, compared to its average volume of 793,917. Structure Therapeutics has a 1 year low of $26.23 and a 1 year high of $62.74. The business has a 50-day moving average price of $35.71 and a 200 day moving average price of $39.09. The company has a market cap of $1.70 billion, a price-to-earnings ratio of -40.19 and a beta of -3.41.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Sandia Investment Management LP acquired a new position in Structure Therapeutics in the 2nd quarter valued at about $39,000. Assetmark Inc. increased its holdings in shares of Structure Therapeutics by 120.0% in the third quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock valued at $58,000 after purchasing an additional 719 shares during the period. Quarry LP acquired a new position in shares of Structure Therapeutics in the second quarter valued at approximately $79,000. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Structure Therapeutics by 60.1% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company’s stock worth $158,000 after purchasing an additional 1,420 shares during the last quarter. Finally, Dearborn Partners LLC acquired a new stake in shares of Structure Therapeutics during the third quarter worth $202,000. 91.78% of the stock is owned by institutional investors and hedge funds.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.